BR0307512A - Métodos para produzir uma linhagem de células contìnua, para gerar e/ou isolar e/ou manter uma cepa de vìrus da doença de marek, para produzir um antìgeno diagnóstico de um vìrus da doença de marek, para preparar uma vacina capaz de induzir proteção contra doença em um vertebrado, e para proteger um vertebrado contra doença, célula ou sua prole, preparação de células, uso das mesmas, vacina, e, uso da mesma - Google Patents

Métodos para produzir uma linhagem de células contìnua, para gerar e/ou isolar e/ou manter uma cepa de vìrus da doença de marek, para produzir um antìgeno diagnóstico de um vìrus da doença de marek, para preparar uma vacina capaz de induzir proteção contra doença em um vertebrado, e para proteger um vertebrado contra doença, célula ou sua prole, preparação de células, uso das mesmas, vacina, e, uso da mesma

Info

Publication number
BR0307512A
BR0307512A BR0307512-5A BR0307512A BR0307512A BR 0307512 A BR0307512 A BR 0307512A BR 0307512 A BR0307512 A BR 0307512A BR 0307512 A BR0307512 A BR 0307512A
Authority
BR
Brazil
Prior art keywords
marek
cell
disease
disease virus
virulent
Prior art date
Application number
BR0307512-5A
Other languages
English (en)
Inventor
Nikolaus Osterrieder
Daniel Schumacher
Original Assignee
Inst Of Molecular Bilogy Fried
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Molecular Bilogy Fried filed Critical Inst Of Molecular Bilogy Fried
Publication of BR0307512A publication Critical patent/BR0307512A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"MéTODOS PARA PRODUZIR UMA LINHAGEM DE CéLULAS CONTìNUA, PARA GERAR E/OU ISOLAR E/OU MANTER UMA CEPA DE VìRUS DA DOENçA DE MAREK, PARA PRODUZIR UM ANTìGENO DIAGNóSTICO DE UM VìRUS DA DOENçA DE MAREK, PARA PREPARAR UMA VACINA CAPAZ DE INDUZIR PROTEçãO CONTRA DOENçA EM UM VERTEBRADO, E PARA PROTEGER UM VERTEBRADO CONTRA DOENçA, CéLULA OU SUA PROLE, PREPARAçãO DE CéLULAS, USO DAS MESMAS, VACINA, E, USO DA MESMA". A invenção proporciona um método para produzir uma linhagem de células continua capaz de suportar o crescimento de uma cepa de vírus da doença de Marek compreendendo infectar ou transfectar uma célula com um vetor compreendendo um ácido nucleico ou fragmento do mesmo de uma cepa de vírus da doença de Marek e cultivar referida célula infectada ou transfectada ou sua prole sob condições adequadas para a expressão de referido ácido nucleico e propagação de referida célula ou de sua prole. De preferência, referido ácido nucleico ou fragmento do mesmo compreende um gene gE de glicoproteína do vírus da doença de Marek ou fragmento funcional do mesmo. A invenção proporciona adicionalmente um método para gerar e/ou de manter uma cepa hipervirulenta e/ou muito virulenta, e ou plus muito virulenta, e ou virulenta e/ou avirulenta de vírus da doença de Marek compreendendo infectar uma célula de acordo com a invenção com uma cepa hipervirulenta, e/ou muito virulenta, e/ou muito virulenta plus, e/ou virulenta e/ou avirulenta de vírus da doença de Marek e cultivar referida célula em condições adequadas para a propagação de referida célula e a geração, manutenção e isolamento de referida cepa hipervirulenta, e/ou muito virulenta, e/ou muito virulenta plus, e/ou virulenta e/ou avirulenta do virus da doença de Marek. A invenção proporciona adicionalmente um método de preparar uma vacina capaz de induzir proteção contra doença, de preferência uma doença associada com vírus da doença de Marek em uma ave compreendendo cultivar uma célula contínua de acordo com a invenção e colher da mesma componentes de cultura de células.
BR0307512-5A 2002-02-06 2003-02-05 Métodos para produzir uma linhagem de células contìnua, para gerar e/ou isolar e/ou manter uma cepa de vìrus da doença de marek, para produzir um antìgeno diagnóstico de um vìrus da doença de marek, para preparar uma vacina capaz de induzir proteção contra doença em um vertebrado, e para proteger um vertebrado contra doença, célula ou sua prole, preparação de células, uso das mesmas, vacina, e, uso da mesma BR0307512A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075480 2002-02-06
PCT/EP2003/001213 WO2003066093A1 (en) 2002-02-06 2003-02-05 A continuous cell line for the production of vaccines

Publications (1)

Publication Number Publication Date
BR0307512A true BR0307512A (pt) 2004-12-07

Family

ID=27675691

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307512-5A BR0307512A (pt) 2002-02-06 2003-02-05 Métodos para produzir uma linhagem de células contìnua, para gerar e/ou isolar e/ou manter uma cepa de vìrus da doença de marek, para produzir um antìgeno diagnóstico de um vìrus da doença de marek, para preparar uma vacina capaz de induzir proteção contra doença em um vertebrado, e para proteger um vertebrado contra doença, célula ou sua prole, preparação de células, uso das mesmas, vacina, e, uso da mesma

Country Status (13)

Country Link
US (1) US20050084503A1 (pt)
EP (1) EP1471937B1 (pt)
JP (1) JP4474164B2 (pt)
CN (1) CN1688335A (pt)
AU (1) AU2003206861B2 (pt)
BR (1) BR0307512A (pt)
CA (1) CA2475326A1 (pt)
DE (1) DE60328456D1 (pt)
DK (1) DK1471937T3 (pt)
ES (1) ES2330425T3 (pt)
IL (1) IL163379A (pt)
RU (1) RU2329060C2 (pt)
WO (1) WO2003066093A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1961814A4 (en) * 2005-11-24 2010-01-06 Univ Osaka Res Found RECOMBINANT POLYVALENT VACCINE
KR20140096162A (ko) * 2008-02-25 2014-08-04 백스터 인터내셔널 인코포레이티드 연속 세포주 제조 방법
CN101875978B (zh) * 2010-02-10 2013-03-27 广西大学 一种区分马立克氏病病毒疫苗毒株与强毒株的鉴别方法
FR2956409A1 (fr) 2010-02-15 2011-08-19 Univ Claude Bernard Lyon Procedes pour optimiser la production virale par l'inactivation ou l'inhibition du gene hipk2 et cellules modifiees pour la production virale
RU2506309C2 (ru) * 2012-03-11 2014-02-10 Екатерина Алексеевна Федорова Способ культивирования миобластов in vitro для получения биомассы миоцитов для пищевых целей
CN103977400B (zh) * 2014-05-29 2015-06-17 南京创启生物科技有限公司 一种用细胞系生产鸡马立克氏病活疫苗的方法
JP2014236748A (ja) * 2014-08-26 2014-12-18 一般財団法人阪大微生物病研究会 組換え多価ワクチン
CN109825497A (zh) * 2019-01-25 2019-05-31 石河子大学 一种新型结核杆菌融合菌株的制备方法及其应用
KR102179463B1 (ko) * 2019-12-06 2020-11-16 서울대학교 산학협력단 닭의 대흉근으로부터 확립된 근아섬유세포주 및 이를 이용한 생리활성물질 스크리닝 방법
US12440556B2 (en) 2020-06-15 2025-10-14 Zoetis Services Llc Genetically modified cell line for production of Marek's disease virus vaccine and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748867A1 (en) * 1995-06-12 1996-12-18 Duphar International Research B.V Marek's disease vaccine
US5989805A (en) * 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
US5827738A (en) * 1995-10-27 1998-10-27 Board Of Trustees Operating Michigan State University Sustainable chick cell line infected with Marek's disease virus
US5833980A (en) * 1995-10-27 1998-11-10 Board Of Trustess Operating Michigan State University Sustainable cell line for the production of the Marek's disease vaccines
EP0884382A3 (en) * 1997-06-10 2000-10-25 Pfizer Products Inc. Processes for preparation of marek's disease virus using continuous mammalian cell lines
US6475770B1 (en) * 1997-06-10 2002-11-05 Pfizer, Inc. Processes for preparation of Marek's Disease using continuous mammalian cell lines
EP1038952A3 (en) * 1998-12-09 2001-06-27 Pfizer Products Inc. Processes for preparation of Marek's Disease Virus using continuous avian cell lines

Also Published As

Publication number Publication date
CA2475326A1 (en) 2003-08-14
RU2004126695A (ru) 2005-06-27
IL163379A (en) 2010-06-30
AU2003206861B2 (en) 2009-04-23
ES2330425T3 (es) 2009-12-10
EP1471937B1 (en) 2009-07-22
DK1471937T3 (da) 2009-11-23
US20050084503A1 (en) 2005-04-21
AU2003206861A2 (en) 2003-09-02
JP4474164B2 (ja) 2010-06-02
RU2329060C2 (ru) 2008-07-20
WO2003066093A1 (en) 2003-08-14
CN1688335A (zh) 2005-10-26
DE60328456D1 (de) 2009-09-03
AU2003206861A1 (en) 2003-09-02
JP2005528888A (ja) 2005-09-29
EP1471937A1 (en) 2004-11-03

Similar Documents

Publication Publication Date Title
Raoult et al. A flea-associated Rickettsia pathogenic for humans
Zou et al. Construction of a highly efficient CRISPR/Cas9-mediated duck enteritis virus-based vaccine against H5N1 avian influenza virus and duck Tembusu virus infection
CN116096403A (zh) 针对pr的致病生物免疫原的通用疫苗卵子生物特异性和跨组保护
Mjaaland et al. Susceptibility and immune responses following experimental infection of MHC compatible Atlantic salmon (Salmo salar L.) with different infectious salmon anaemia virus isolates
Hanke et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA-and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya
KR20230011369A (ko) mRNA 또는 mRNA 조성물, 및 이의 제조 방법 및 이의 용도
CN101300363A (zh) 用于用具有改善的免疫原性的prrsv抗原免疫接种动物的方法和组合物
Tucker et al. Evaluation of porcine cytomegalovirus as a potential zoonotic agent in xenotransplantation
JP7268055B2 (ja) ヒトｄｃ細胞増幅方法及びヒトｄｃ細胞資源バンク
US6060457A (en) DNA plasmid vaccine for immunization of animals against BVDV
US20010014673A1 (en) Live vaccine against brucellosis
RU2004126695A (ru) Непрерывная клеточная линия для получения вакцин
JP2002247979A (ja) マレック病ワクチンおよびその製造方法
Einsele et al. CMV-specific immunotherapy
CA2634144A1 (en) Novel fish pathogen
Kreiter et al. FLT3 ligand as a molecular adjuvant for naked RNA vaccines
CN101768575B (zh) 双表达g基因的重组狂犬病病毒的构建及其生物学特性分析
HU227667B1 (en) Novel expression vectors and uses thereof
CN109414023A (zh) 用嵌合脊髓灰质炎病毒激活抗原呈递细胞的组合物和方法
EP0689596B1 (en) Stimulation of immune response by viral protein
CN115044562B (zh) 一种嵌合表达分子佐剂的重组狂犬病病毒及其制备方法与应用
Li et al. Immunogenicity assessment of rift valley fever virus virus-like particles in BALB/c mice
KR102365039B1 (ko) 부유세포 배양에 적응된 A/ASIA/Sea-97 유전형 구제역 바이러스 백신주 및 이의 제조방법
CN100346827C (zh) 由caev和hiv－1遗传元件组成的病毒嵌合体
Steinbach et al. Dendritic cells presenting equine herpesvirus-1 antigens induce protective anti-viral immunity

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 9A ANUIDADE.